Post Bactrim Severe Allergic Reaction can be Stevens Johnson Syndrome: Here is what you should do asap:

The first and most critical step is immediate discontinuation of Bactrim (sulfamethoxazole-trimethoprim) — early culprit-drug withdrawal is the single most important intervention and is associated with better prognosis.[1][2] The patient should then be urgently transferred to a burn unit or ICU with dermatology expertise for multidisciplinary supportive care.[3][4] Sulfonamides are among the highest-risk drug classes for SJS/TEN.[2]

Below is a system-by-system, phased treatment plan organized from most critical to least, based on current evidence and guidelines.

ACUTE PHASE (Days 0–3): Stabilization & Assessment

1. Skin / Integumentary (Highest Priority)

- Immediately stop Bactrim and all non-essential medications.[1]

- Assess % body surface area (BSA) of epidermal detachment to classify severity: SJS (<10%), SJS/TEN overlap (10–30%), TEN (>30%).[2]

- Leave detached epidermis intact — it acts as a biological dressing protecting the dermis.[5]

- Apply non-adhesive dressings (e.g., silver-releasing antimicrobial dressings, changed every 3 days); use mupirocin-coated petrolatum gauze for facial involvement.[5][4]

- Wound cleansing with sterile saline or antiseptics (chlorhexidine); no prophylactic systemic antibiotics.[1][6]

- Raise ambient room temperature to ≥28°C to prevent hypothermia from impaired thermoregulation.[1]

2. Hemodynamics / Fluid Resuscitation

- Begin IV crystalloid resuscitation immediately, guided by urine output (target ~0.5–1 mL/kg/hr). Fluid needs are generally less than equivalent-BSA burns (typically ~2 mL/kg/% BSA/day rather than 4 mL/kg/% BSA).[5][4]

- Place IV lines in uninvolved skin.[1]

- Monitor electrolytes, albumin, and renal function daily; adjust fluids accordingly.[1][5]

3. Eyes / Ophthalmology (Urgent — Within Hours)

- Ophthalmology consultation within 24 hours of admission — ocular involvement occurs in 40–84% of cases and early intervention is critical to prevent blindness.[7][8]

- Start preservative-free artificial tears hourly, vitamin A ointment, and topical corticosteroid eye drops (e.g., dexamethasone or betamethasone 0.1%).[7][8]

- Perform pseudomembrane removal (lysis of adhesions) daily.[8]

- For severe/extremely severe ocular involvement: urgent amniotic membrane transplantation (AMT) — this significantly reduces long-term corneal scarring, symblepharon, and visual loss (BCVA ≥20/40 in 92% with protocol care vs. 33% without).[9][10][11]

4. Airway / Pulmonary

- Assess for laryngeal and bronchial mucosal involvement (hoarseness, dyspnea, cough).[1]

- Avoid routine intubation — systematic mechanical ventilation is associated with higher in-hospital mortality. Intubate only for clear respiratory failure.[1]

- Monitor oxygen saturation continuously; pulmonary infection is significantly associated with severe laryngeal lesions.[1]

5. Pain Management

- Opioid analgesia (e.g., IV morphine or patient-controlled analgesia) for skin debridement and mucosal care.[1][6]

- Anxiolytics (e.g., low-dose benzodiazepines) for PTSD prevention.[1]

- Respiratory monitoring required with opioid use.[1]

6. Nutrition / GI

- Nutritional screening within 24 hours.[5]

- Begin high-calorie, high-protein enteral feeding via nasogastric tube if oral intake is limited by oral mucosal erosions.[1][5]

- Oral feeding preferred when feasible; enteral preferred over parenteral to reduce bacterial translocation risk.[5]

7. Renal / Metabolic

- Monitor BUN, creatinine, electrolytes, glucose, bicarbonate daily.[1][12]

- Hypovolemia-driven AKI is common; aggressive fluid resuscitation is protective.[1]

8. Prognostic Scoring

- Calculate SCORTEN within 24 hours of admission (7 parameters: age >40, malignancy, HR >120, BSA >10%, BUN >28 mg/dL, glucose >252 mg/dL, bicarbonate <20 mEq/L). Predicted mortality ranges from 3.2% (score 0–1) to 90% (score ≥5).[13][14][12]

---

SUBACUTE PHASE (Days 3–14): Active Disease Management

Skin

- Continue wound care with dressing changes every 2–3 days; disease progression typically plateaus by day 7–10.[1][4]

- Re-epithelialization usually begins ~1 week after onset and takes up to 3 weeks.[1]

- Monitor for signs of wound infection (erythema, purulence, fever) — sepsis is the leading cause of death. Culture wounds if infection suspected; treat only documented infections.[1][6]

Immunomodulatory Therapy (Consider Days 1–5)

- No RCT-validated curative treatment exists. Options with the most supportive (though low-certainty) evidence:[1][15]

- Cyclosporine 3 mg/kg/day orally (or 1 mg/kg/day IV), tapered over 10 days — may reduce disease progression (38% progression vs. 65% with IVIG).[1][15]

- Etanercept 25–50 mg SC — may reduce mortality vs. corticosteroids (low-certainty evidence).[1][15]

- IVIG (0.2–1 g/kg/day × 3 days) — evidence for mortality benefit is conflicting.[15][1]

- Thalidomide is contraindicated — increased mortality in the only RCT.[15][1]

Eyes

- Continue daily ophthalmologic examination, pseudomembrane lysis, topical steroids, and lubrication.[8]

- Repeat AMT every 10–14 days if severe inflammation persists.[11]

Oral / ENT Mucosa

- Chlorhexidine mouthwash daily.[6]

- Topical lidocaine gel for pain relief.[15]

- ENT evaluation for nasopharyngeal and esophageal involvement.[1]

Genitourinary

- Daily examination for genital erosions; apply emollients and non-adhesive dressings.

- Gynecology consultation for female patients to prevent vaginal synechiae.[1]

Infection Surveillance

- Blood cultures, wound cultures, and urine cultures if fever develops.[6]

- Avoid prophylactic antibiotics — they increase resistance without proven benefit.[1]

---

RECOVERY PHASE (Weeks 2–6): Healing & Rehabilitation

- Skin: Re-epithelialization completes over 2–3 weeks. Transition to emollients and photoprotection. Average time to complete skin healing is ~14 days in favorable cases.[1][4]

- Eyes: Continue aggressive lubrication; taper topical steroids gradually under ophthalmology guidance.

- Nutrition: Transition from enteral to oral feeding as mucosal healing permits.

- Physical therapy: Early mobilization to prevent deconditioning and contractures.

- Psychiatry: Screen for PTSD, depression, and anxiety — these affect nearly 50% of survivors.[16]

---

CHRONIC PHASE (Months 2–60+): Long-Term Follow-Up

Multidisciplinary follow-up is mandatory at months 2, 6, 12, and annually for at least 5 years.[1]

The following figure illustrates the frequency of long-term sequelae across organ systems in SJS/TEN survivors:

Key chronic complications by system:

- Cutaneous (>80% of survivors): Dystrophic scars, hyperpigmentation, photosensitivity, nail loss, alopecia.[1][16]

- Ocular (up to 65%): Chronic dry eye, symblepharon, corneal scarring, visual loss — may require scleral lenses or mucous membrane grafts.[1][7]

- Oral (≈50%): Sialadenitis, tooth decay, dental agenesia.[1][16]

- Genital: Synechiae, strictures — gynecology/urology follow-up.[1]

- Pulmonary: Bronchiolitis obliterans, chronic cough.[1]

- Renal: Monitor for chronic kidney disease if AKI occurred acutely.[17]

- Psychiatric (≈45–50%): Depression, anxiety, PTSD — screen at every visit.[1][16]

Drug Allergy Documentation

- Permanently document allergy to sulfonamides (sulfamethoxazole-trimethoprim) and all structurally related drugs.

- Patch testing at 6 months post-resolution to confirm the causative agent.[1]

---

Key Takeaway: SJS management is fundamentally supportive care in an expert center — there is no proven curative systemic therapy.[15][3] The pillars are: (1) immediate drug withdrawal, (2) burn-unit-level wound and fluid management, (3) early aggressive ophthalmologic intervention, and (4) prolonged multidisciplinary follow-up to address the high burden of chronic sequelae.

References

1. Severe Cutaneous Adverse Reactions to Drugs. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Lancet (London, England). 2017;390(10106):1996-2011. doi:10.1016/S0140-6736(16)30378-6.
2. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Clinical Reviews in Allergy & Immunology. 2018;54(1):147-176. doi:10.1007/s12016-017-8654-z.
3. Diagnosing and Managing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017-2023. Ingen-Housz-Oro S, Matei I, Gaillet A, et al. The Journal of Investigative Dermatology. 2025;145(7):1589-1603. doi:10.1016/j.jid.2024.06.1295.
4. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a Burn Unit: A 15-Year Experience. McCullough M, Burg M, Lin E, Peng D, Garner W. Burns : Journal of the International Society for Burn Injuries. 2017;43(1):200-205. doi:10.1016/j.burns.2016.07.026.
5. Diagnosis and Management of Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Patients: A Systematic Review of Clinical Guidelines and Consensus Statements. Creighton R, Gupta S, Langille C, Sutherland A. Pediatric Dermatology. 2026 May-Jun;43(3):579-589. doi:10.1111/pde.70149.
6. Microbiological findings and antibacterial therapy in Stevens–Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center. Tocco-Tussardi I, Huss F, Presman B. Journal of Cutaneous Pathology. 2017;44(5):420-432. doi:10.1111/cup.12894.
7. Updates on the Ocular Manifestations and Treatment of SJS/TEN. Sotozono C, Ueta M. Allergology International : Official Journal of the Japanese Society of Allergology. 2025;74(3):356-360. doi:10.1016/j.alit.2025.05.003.
8. Management of Ocular Involvement in the Acute Phase of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: French National Audit of Practices, Literature Review, and Consensus Agreement. Thorel D, Ingen-Housz-Oro S, Royer G, et al. Orphanet Journal of Rare Diseases. 2020;15(1):259. doi:10.1186/s13023-020-01538-x.
9. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome: A Randomized Control Trial. Sharma N, Thenarasun SA, Kaur M, et al. Ophthalmology. 2016;123(3):484-91. doi:10.1016/j.ophtha.2015.10.027.
10. Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Shanbhag SS, Rashad R, Chodosh J, Saeed HN. American Journal of Ophthalmology. 2019;208:331-341. doi:10.1016/j.ajo.2019.07.006.
11. Treatment of Acute Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Using Amniotic Membrane: A Review of 10 Consecutive Cases. Gregory DG. Ophthalmology. 2011;118(5):908-14. doi:10.1016/j.ophtha.2011.01.046.
12. Predictive Value of a Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) Factors for in-Hospital Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Nikitina E, Dushkin A, Streltsov Y, et al. Frontiers in Medicine. 2025;12:1735242. doi:10.3389/fmed.2025.1735242.
13. Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: The Role of Novel Inflammatory Markers and Proposed Revision of SCORTEN (Re-SCORTEN). Koh HK, Fook-Chong SMC, Lee HY. JAMA Dermatology. 2022;158(2):160-166. doi:10.1001/jamadermatol.2021.5119.
14. Accuracy of SCORTEN to Predict the Prognosis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review and Meta-Analysis. Torres-Navarro I, Briz-Redón Á, Botella-Estrada R. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(9):2066-2077. doi:10.1111/jdv.16137.
15. Systemic Interventions for Treatment of Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS/TEN Overlap Syndrome. Jacobsen A, Olabi B, Langley A, et al. The Cochrane Database of Systematic Reviews. 2022;3:CD013130. doi:10.1002/14651858.CD013130.pub2.
16. Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Hoffman M, Chansky PB, Bashyam AR, et al. JAMA Dermatology. 2021;157(6):712-715. doi:10.1001/jamadermatol.2021.1136.
17. Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Ten-Year Retrospective Study of 103 Cases. Zhou L, Lu Y, Zou Y, et al. Clinical and Experimental Dermatology. 2025;:llaf278. doi:10.1093/ced/llaf278.